The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products (original) (raw)
Strategies for Managing Heparin Therapy in Patients with Antiphospholipid Antibody Syndrome
maureen smythe
Pharmacotherapy, 2011
View PDFchevron_right
Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings
W. Weitschies, S. Alban
Thrombosis Research, 2008
View PDFchevron_right
Antiplatelet Factor 4—Heparin Antibodies in Patients with Antiphospholipid Antibodies
Swapan Dasgupta
Thrombosis Research, 1999
View PDFchevron_right
Prevalence, isotype, and functionality of antiheparin–platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia
Sarfraz Ahmad
Thrombosis Research, 2002
View PDFchevron_right
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?
Ludovic Drouet
Targeted Oncology, 2012
View PDFchevron_right
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
john paul
Journal of Clinical Investigation, 1994
View PDFchevron_right
Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins
Gabriela Allan Canto
British Journal of Dermatology, 2009
View PDFchevron_right
Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients
Mahmut Yüksel
Turkish journal of haematology : official journal of Turkish Society of Haematology, 2009
View PDFchevron_right
Thrombosis in Suspected Heparin-Induced Thrombocytopenia Occurs More Often With High Antibody Levels
John Fanikos
American Journal of Medicine
View PDFchevron_right
Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis
Giangiacomo Torri
Journal of Thrombosis and Haemostasis
View PDFchevron_right
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
Jose Nicolau
Journal of Thrombosis and Thrombolysis, 2012
View PDFchevron_right
Heparin-induced thrombocytopenia: Pathophysiology and new treatment options
Job Harenberg
Pathophysiology of Haemostasis and Thrombosis, 2002
View PDFchevron_right
Heparin/PF4 antibodies formation after heparin treatment: Temporal aspects and long-term follow-up
Giuseppe Ambrosio
American Heart Journal, 2009
View PDFchevron_right
Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytope- nia in medical patients Medikal hastalarda anti-heparin trombosit faktör 4 antikor ve heparine bağli trombositopeni sikliği
Mahmut Yüksel
2009
View PDFchevron_right
Heparin-induced thrombocytopenia and thrombosis
Marjut Kauppila
Clinical Cardiology, 2004
View PDFchevron_right
Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia
B. Chong
Thrombosis Research, 1996
View PDFchevron_right
Hypersensitivity reactions to low molecular weight heparins: different patterns of cross-reactivity in 3 patients
Danica Juricic Nahal
Canadian Journal of Physiology and Pharmacology, 2018
View PDFchevron_right
Increased Prevalence of Antiheparin Platelet Factor 4 Antibodies in Patients May Be Due to Contaminated Heparin
Hussain Khan
Clinical and Applied Thrombosis/Hemostasis, 2009
View PDFchevron_right
Heparin-Dependent Antibodies and Thrombosis without Heparin-Induced Thrombocytopenia
Ryan Hobbs
Pharmacotherapy, 2008
View PDFchevron_right
Autoantibodies to heparan sulfate proteoglycans
Yves Renaudineau
Autoimmunity Reviews, 2002
View PDFchevron_right
Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells
Babette Weksler
International Immunology, 2002
View PDFchevron_right
Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
Prof. Fahad A S Aleidan
Mediterranean Journal of Hematology and Infectious Diseases, 2015
View PDFchevron_right
Thrombotic events in patients with antiplatelet factor 4/heparin antibodies
Giuseppe Ambrosio
Heart, 2009
View PDFchevron_right
Positive Heparin/PF4 Antibodies and High Mortality Rate: a Retrospective Case-Series Analysis
Kerem Oral
Brazilian Journal of Cardiovascular Surgery, 2020
View PDFchevron_right
Update on Mechanisms, Pathogenicity, Heterogeneity of Presentation, and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia
Jean AMIRAL
Anticoagulation drugs - the Current State of the Art [Working Title]
View PDFchevron_right
Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172
B. Chong
Blood, 1989
View PDFchevron_right
Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis
Sarfraz Ahmad
Molecular and Cellular Biochemistry, 2000
View PDFchevron_right
Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
Jean AMIRAL
Transfusion, 1994
View PDFchevron_right
Heparin‐Induced Thrombocytopenia: Pathophysiology, Diagnosis, and Treatment Monitoring
Dimitrios Stylos
Drug Development Research, 2013
View PDFchevron_right
Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia
Vishal Jindal
Journal of Blood Medicine, 2020
View PDFchevron_right
Laboratory Diagnosis of Heparin-Induced Thrombocytopenia in Asian Indians as Investigated With Functional and Immunologic Methods
Rafeeq Ahmed
Clinical and Applied Thrombosis-hemostasis, 2004
View PDFchevron_right
Heparins: Clinical use and laboratory monitoring
Julia Davis
Laboratory Medicine, 2010
View PDFchevron_right
Why Is Heparin, Despite Being an Anticoagulant, Rarely Associated with Blood Clotting? A Systematic Review
Liberty Omorogbe
2021
View PDFchevron_right